Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
France uses tax to put pressure on hepatitis C drug prices

France will tax drugmakers whose costly hepatitis C drugs threaten to throw off course its healthcare budget, the government has said, heaping pressure on pharmaceutical companies like Gilead Sciences to cut their prices.

Published
18 hours ago
From
Reuters
After Patient's Death, Study Shows HCV Drug Cardiotoxic in 14 of 34 Treated Patients

The development of BMS-986094 (Bristol-Myers Squibb), a nucleotide-polymerase inhibitor for the treatment of chronic hepatitis C (HCV) infection, was terminated back in August 2012, but a new retrospective review analyzing adverse events provides an in-depth look at the cardiotoxicity associated with the investigational agent. The findings may have profound implications for other drugs in late-stage testing or others approved for use.

Published
29 September 2014
From
Medscape (requires registration)
European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults

Gilead Sciences, Inc. GILD, +0.97% today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for Harvoni®,an investigational once-daily tablet combining the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg, for the treatment of chronic hepatitis C virus (HCV) infection in adults.

Published
29 September 2014
From
Gilead press release
Why Gilead’s Recent Deal with Generic Producers for its Hepatitis C Drugs (Sofosbuvir and Ledipasvir) is a Sham

Under the pretext of increasing access to its hepatitis C treatment, the new deal signed by Gilead for their HCV drugs sofosbuvir (Sovaldi©) and ledipasvir hides a clear strategy to prevent fair generic competition. The International Treatment Preparedness Coalition (ITPC) denounces Gilead’s strategy to block generic competition.

Published
25 September 2014
From
ITPC
NICE consults on draft guidance on the drug simeprevir (Olysio) for treating hepatitis C

In draft guidance published today healthcare guidance body NICE has recommended simeprevir (Olysio, Janssen) as a treatment option for some people with chronic hepatitis C.

Published
25 September 2014
From
NICE
As Gilead Mulls Price of Next Hepatitis C Drug, Top Activist Refutes "Bogus" Math

Sovaldi, the hepatitis C drug that costs US$1,000 a pill and US$84,000 for a full course of treatment, is about to look a little bit more reasonable by comparison. According to industry analysts, the price for Gilead's next hepatitis C drug (a combination of Sovaldi and the experimental drug ledipasvir), which the U.S. Food and Drug Administration may approve as soon as next month, could come with a price tag of US$95,000 for a course of treatment.

Published
24 September 2014
From
TheBody.com
Hepatitis C: Sit in of European patients to request access to new medicines, on occasion of the informal meeting of European Health Ministers in Milan

In support of the Call to EU Ministers of Health and CEOs of Abbvie, BMS, Gilead, Janssen and Merck/MSD regarding Universal Access to Curative Hepatitis C Treatment in the EU an beyond (attached), EPAC, Lila and Nadir with the support of the subscribers of the call, organized a “Sit-In” of people living with hepatitis C and their allies on the 22nd of September, at the Mico Conference Center, in Milan, starting at 11:20 am, to advocate for, and demand, a clear political and public health commitment and leadership from the twenty eight member states of the European Union

Published
22 September 2014
From
EATG
The new $84,000 hepatitis C treatment is losing momentum, for now

Data released by CVS Health on Tuesday show that use of Sovaldi has slowed down since May after the drug's record-setting start last December. The slowdown can partly be explained by the health-care industry's anticipation of more hepatitis C treatments soon hitting the market, including another one from Gilead that could gain FDA approval any day now.

Published
22 September 2014
From
Washington Post
Thousands register for new hepatitis C drug in Egypt sold at 99 percent discount

On Thursday, Gamal Esmat, member of the Egyptian National Committee on Viral Hepatitis told Aswat Masriya that around 1,7000 people had registered hours after online registration opened on the Health Ministry’s website.

Published
19 September 2014
From
Egyptian Streets
Community Leaders, HIV Doctors Oppose Hepatitis C Treatment Barriers

A coalition of hepatitis C advocacy organizations and medical providers has issued an open letter to the Secretary of Health and Human Services calling for an end to restrictions on access to hepatitis C treatment by private insurers and public payers seeking to avoid the cost of newly approved direct-acting antivirals. HIV medical providers also called for reducing barriers to treatment, including restrictions on which medical specialists may treat people with hepatitis C.

Published
17 September 2014
From
HIVandhepatitis.com
← First12345...44Next →

Filter by country